A phase I study investigated the therapeutic use of samalizumab (ALXN6000) as a CD200-CD200R immune checkpoint inhibitor in chronic lymphocytic leukemia (CLL) and multiple myeloma. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.